Design Therapeutics, Inc DSGN Stock Price, Quote & News

Table Of Content

• Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track
• Design Therapeutics to Webcast Fourth Quarter and Full Year 2023 Financial Results and Comprehensive Portfolio Update
• Alphabet’s New Dividend: What Investors Need to Know
• Design Therapeutics (DSGN) Stock Price, News & Analysis
• Market Updates

Design’s lead program is focused on the treatment of Friedreich ataxia, followed by a program in myotonic dystrophy type-1 and discovery efforts for multiple other serious degenerative disorders caused by nucleotide repeat expansions. For more information, please visit designtx.com. Design Therapeutics, Inc a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. Design Therapeutics last released its earnings data on March 19th, 2024. The reported ($0.21) earnings per share for the quarter, beating the consensus estimate of ($0.32) by $0.11.

Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track

Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially and adversely and reported results should not be considered as an indication of future performance. These forward-looking statements speak only as of today's date and the Company undertakes no obligation to revise or update any statement made today. I encourage you to review all of the Company's filings with the Securities and Exchange Commission concerning these and other matters.

Design Therapeutics to Webcast Fourth Quarter and Full Year 2023 Financial Results and Comprehensive Portfolio Update

Corton Capital Inc. increased its stake in shares of Design Therapeutics by 56.6% in the third quarter. Corton Capital Inc. now owns 27,134 shares of the company's stock worth $64,000 after purchasing an additional 9,811 shares in the last quarter. Algert Global LLC boosted its position in shares of Design Therapeutics by 83.3% during the third quarter. Algert Global LLC now owns 35,620 shares of the company's stock worth $84,000 after acquiring an additional 16,190 shares during the last quarter. Finally, Jump Financial LLC boosted its position in shares of Design Therapeutics by 284.7% during the third quarter.

Alphabet’s New Dividend: What Investors Need to Know

Since we're talking about the upcoming discussion with the FDA. I'm just curious if you have any lingering questions or actually items you'd like to discuss with the agency around midyear. Phase IIb study, yes, we're going to have a Type C meeting with the FDA later this quarter.

Financial Strength

This makes it difficult to properly value the company and its stock, as Design Therapeutics has no price-to-earnings (P/E) ratio since it has no earnings. DSGN dropped 45% in premarket trading Tuesday after the biopharma company reported mixed results from an early-stage trial of a treatment for Friedreich ataxia, a ge... Yes, I think it's an issue for all doses.

And I think probably six months or nine months would be the two most likely candidates for duration of the Phase IIb. Shares of Design Therapeutics stock traded down $0.01 during trading on Wednesday, hitting $3.65. The stock had a trading volume of 192,880 shares, compared to its average volume of 262,557. The stock has a market cap of $206.19 million, a PE ratio of -3.04 and a beta of 1.82.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Nisa Investment Advisors LLC increased its stake in shares of Design Therapeutics by 38,433.3% in the fourth quarter. Nisa Investment Advisors LLC now owns 11,560 shares of the company's stock worth $31,000 after purchasing an additional 11,530 shares in the last quarter. SG Americas Securities LLC purchased a new stake in shares of Design Therapeutics in the third quarter worth $47,000.

And so we would hope to be able to start the next study a Phase IIb study seems seems likely of, but we would look to start to that later in the year. Probably fourth quarter would be the timing for that study. Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Highlights important summary options statistics to provide a forward looking indication of investors' sentiment.

Design Therapeutics Highlights Clinical and Research Progress and Reports First Quarter 2022 Financial Results

But and generally, the larger partners like to see more data as programs evolve. But again, that's not a I don't think that's a mandatory requirement right now. Oh, hey, congrats on all the progress and thank you for providing this update for subcu VK. What kind of data should we expect in 2Q?

We are getting a lot of questions around that given the supply problems that current manufacturers have with their own therapies right now. So I just wanted to know if you're going into this on with that thought in mind. And on the second is, I guess, given some of the additional benefits that we lost drugs are having, whether it's on CV risk or hypertension or kidney disease and sleep apnea?

And with respect to less-frequent dosing, I mean, that's part of the PK data that we will receive. If it looks like we're in a therapeutic range at some period after the last dose, maybe that will be feasible. Our strategy and we would look to incorporate that into a subsequent trial.

MDXG Stock Quote Price and Forecast - CNN

MDXG Stock Quote Price and Forecast.

Posted: Fri, 23 Feb 2024 18:13:42 GMT [source]

I mean there throughout the supply chain of solvents, whatever is needed for solid phase synthesis, a fill-and-finish materials. So it's a pretty of zero shortfall right now. But again, we don't think that's going to be a terminal state for for this class of compounds. When you look at the market opportunity, that incentive is pretty high to figure out these problems. Yes, thanks, Andy, for the flat to bottom, you know, from from what we've seen right now, the Phase two B studies that were performed with the semaglutide Enterra's appetite had not plateaued prior to the registration studies being initiated.

View Design Therapeutics' Short Interest. Don’t get the wrong idea here — I fully respect Design Therapeutics’ drive to advance its research programs. As the old saying goes, the trend is your friend — though it can also be your enemy if you’re holding a toxic stock. Also, bear in mind that Design Therapeutics could eventually get delisted from the Nasdaq exchange if the share price falls below $1 and stays there for a prolonged period of time. This is Nick on for Steve on we have a question related to animals on manufacturing.

Are you able to specify what materials or factors are most gaining to ramp up commercial supply of two seven three five? And would this only be a potential issue for the higher doses of the oral formulation? Well, we're not going to disclose the nature of the conversations, but we're interested in study design and duration. And going back to your question about it, understanding that the ideal duration prior to Phase three. So those are those are our key questions.